Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 53.7%

Neg 0% Neu 0% Pos 53.7%

Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.